The Power of Innovation:
The Monthly Dapivirine Ring
IPM designed the dapivirine vaginal ring to address a gap in the HIV prevention portfolio with a discreet, long-acting and woman-controlled product. Women insert the ring and leave it in place for a month—“set it and forget it.”
After two Phase III clinical trials, The Ring Study and ASPIRE, found in 2016 that the ring reduced women’s HIV risk, many former participants enrolled into subsequent open-label extension studies (OLEs) called DREAM and HOPE, respectively, where they received the active ring. The Ring Study and DREAM were led by IPM, and ASPIRE and HOPE were conducted by IPM’s clinical trials partner, the US National Institutes of Health-funded Microbicide Trials Network (MTN).
In 2019, the DREAM and HOPE OLEs reported encouraging final results: a strong safety profile, increased adherence compared to the Phase III trials, and based on modeling data, an estimated risk reduction of 63% in DREAM and 39% in HOPE. Although the modeling data are limited due to the lack of placebo comparison groups, they suggest an upward trend in HIV risk reduction that we hope to build on pending country approvals for the ring and its rollout.